Click a keyword to view all the abstracts on this site tagged with that keyword.
- bone marrow lesions and rheumatoid arthritis (RA)
- bone metabolism
- bone metabolism and bone remodeling mediators
- Bone metabolism and rheumatoid arthritis (RA)
- Bone metabolism and spondylarthritis
- bone mineral density and frailty
- bone remodeling
- bone remodeling and biopsies
- bone remodeling and fractures
- bone remodeling and prostaglandins
- bone remodeling and rheumatoid arthritis (RA)
- bone remodeling and spondylarthropathy
- Bone turnover markers
- bone turnover markers and bone density
- bone turnover markers and inflammation
- bone turnover markers and modified stoke ankylosing spondylitis spinal score (MSASSS)
- Bone turnover markers and systemic lupus erythematosus (SLE)
- Bortezomib
- Bortezomib and SLE
- botulinum toxin
- botulinum toxin and pain management
- botulinum toxin and treatment
- Bowel
- BR3
- Brain
- Brain Biopsy
- Brain-derived Neurotrophic Factor and Neuropsychological Assessment
- BRD4 and systemic sclerosis
- Bromodomain
- bronchoalveolar lavage fluid and morbidity and mortality
- BTK
- BTK and rheumatoid arthritis (RA)
- business
- business and rheumatoid arthritis (RA)
- C protein-induced myositis
- C Reactive Protein
- C Reactive Protein and synovitis
- C-reactive protein (CRP)
- C-reactive protein (CRP) and Aging
- C-reactive protein (CRP) and autoantibodies
- C-reactive protein (CRP) and Disease Activity
- C-reactive protein (CRP) and interleukins (IL)
- C-reactive protein (CRP) and laboratory and imaging evaluation
- C-reactive protein (CRP) and renal disease
- C-reactive protein (CRP) and rheumatoid arthritis (RA)
- C-reactive protein (CRP) and scleroderma
- C1q
- cachexia and myostatin
- cadherin-11
- Cadherins
- calcinosis
- calcinosis and dermatomyositis
- Calcinosis and juvenile dermatomyositis
- calcinosis and pyrophosphate
- Calcinosis and scleroderma
- Calcinosis and systemic sclerosis
- Calcinosis and treatment
- Calcitonin
- Calcium
- calcium and cardiovascular disease
- Calcium and denosumab
- Calcium and mesenchymal stem cells
- calcium and rheumatoid arthritis (RA)
- calcium and signal transduction
- calcium and tendonitis/bursitis
- Calcium pyrophosphate dihydrate (CPPD)
- Calcium pyrophosphate dihydrate (CPPD) and chondrocytes
- Calcium pyrophosphate dihydrate (CPPD) and diagnosis
- calcium pyrophosphate dihydrate (CPPD) and Electronic Health Record
- Calcium pyrophosphate dihydrate (CPPD) and pseudogout
- Calcium pyrophosphate dihydrate (CPPD) and rheumatoid arthritis (RA)
- Calcium pyrophosphate dihydrate (CPPD) and synovial fluid
- calcium pyrophosphate dihydrate (CPPD) and ultrasound
- calcium signaling
- Calgranulin
- CALIPER and survival
- calprotectin
- calprotectin and atherosclerosis
- calprotectin and longitudinal studies
- CaMKIV and Treg
- canakinumab
- canakinumab and Biologics
- Canakinumab and caregivers
- canakinumab and corticosteroids
- canakinumab and familial Mediterranean fever
- canakinumab and fever
- canakinumab and interleukins (IL)
- canakinumab and juvenile idiopathic arthritis (JIA)
- canakinumab and monoclonal antibodies
- Canakinumab and safety
- canakinumab and tocilizumab
- canakinumab and treatment
- Cancer
- cancer and cancer treatments
- cancer and clinical practice
- Cancer and cutaneous lupus erythematosus
- cancer and histopathologic
- cancer and human papillomavirus (HPV)
- cancer and immunosuppressants
- Cancer and inflammatory arthritis
- cancer and Janus kinase (JAK)
- cancer and lymphopenia
- cancer and malignancy
- Cancer and myositis
- cancer and nonsteroidal antiinflammatory drugs (NSAIDs)
- cancer and Oncology
- cancer and patient preferences
- Cancer and polymyositis/dermatomyositis (PM/DM)
- Cancer and psoriatic arthritis
- cancer and registry
- cancer and Reproductive Health
- cancer and rheumatoid arthritis (RA)
- cancer and scleroderma
- cancer and systemic lupus erythematosus (SLE)
- Cancer treatments
- cancer treatments and immune response
- cancer treatments and Immunotherapy
- cancer treatments and inflammatory arthritis
- cancer treatments and morbidity and mortality
- cancer treatments and myositis
- Cancer treatments and osteoporosis
- cancer treatments and rheumatoid arthritis (RA)
- cancer treatments and rheumatologic disease
- Cancer treatments and rituximab
- cancer treatments and sarcoidosis
- cancer treatments and systemic sclerosis
- cannabidiol
- cannabinoid
- cannabinoid and clinical trials
- cannabinoid and patient-reported outcome measures
- Capillaroscopy
- capillaroscopy and chemokines
- capillaroscopy and nailfold capillaroscopy
- capillaroscopy and scleroderma
- Capillaroscopy and systemic lupus erythematosus (SLE)
- capillaroscopy and systemic sclerosis
- capillary microscopy
- capillary microscopy and autoantibodies
- capillary microscopy and connective tissue diseases
- carboxypeptidase B and rheumatoid arthritis (RA)
- card9
- Cardiac amyloidosis (CA)
- cardiac and anti-TNF therapy
- Cardiac fibrosis
- cardiac MRI
- Cardiac Sarcoidosis
- cardiac structure and follow up
- cardiotoxicity and BNP
- Cardiovascular and rheumatoid arthritis
- Cardiovascular disease
- cardiovascular disease and administrative databases
- cardiovascular disease and antiphospholipid antibodies
- cardiovascular disease and assessment
- cardiovascular disease and big data
- cardiovascular disease and biomarkers
- cardiovascular disease and cholesterol
- cardiovascular disease and Co-morbidities
- cardiovascular disease and comorbidity
- cardiovascular disease and computed tomography (CT)
- cardiovascular disease and CT scan
- Cardiovascular disease and cutaneous lupus erythematosus
- cardiovascular disease and death
- cardiovascular disease and depression
- cardiovascular disease and diabetes
- Cardiovascular disease and diffuse idiopathic skeletal hyperostosis (DISH)
- cardiovascular disease and Disease Activity
- cardiovascular disease and endothelial cells
- cardiovascular disease and epidemiologic methods
- cardiovascular disease and exercise
- cardiovascular disease and extraarticular manifestations
- cardiovascular disease and eye
- cardiovascular disease and fibrosis
- cardiovascular disease and genetic disorders
- cardiovascular disease and genetics
- Cardiovascular disease and giant cell arteritis
- Cardiovascular disease and glucocorticoids
- cardiovascular disease and gout
- cardiovascular disease and high risk
- Cardiovascular disease and hydroxychloroquine
- cardiovascular disease and hyperuricemia
- cardiovascular disease and immunoglobulin (IG)
- cardiovascular disease and inflammation
- cardiovascular disease and inflammatory arthritis
- Cardiovascular disease and juvenile arthritis
- cardiovascular disease and juvenile dermatomyositis
- Cardiovascular disease and juvenile idiopathic arthritis (JIA)
- cardiovascular disease and juvenile SLE
- cardiovascular disease and large vessel vasculitis
- cardiovascular disease and lipids
- cardiovascular disease and longitudinal studies
- cardiovascular disease and meta-analysis
- cardiovascular disease and metabolism
- cardiovascular disease and methotrexate (MTX)
- cardiovascular disease and morbidity and mortality
- cardiovascular disease and mycophenolate mofetil
- cardiovascular disease and myocardial infarction
- Cardiovascular disease and myositis
- cardiovascular disease and nonsteroidal antiinflammatory drugs (NSAIDs)
- Cardiovascular disease and nutrition
- cardiovascular disease and obesity